Skip to content
Research Article Open access CC BY 4.0

Effect of Fixed-Dose Combination of Efonidipine + S(-) Metoprolol in Indian Hypertensive Patients

Bhupesh Dewan, Siddheshwar Shinde, Shweta Kondekar

Cardiology and Angiology: An International Journal · pp. 448–458 · Published 21 Dec 2022

10.9734/ca/2022/v11i4300

Abstract

Aim: To evaluate the antihypertensive efficacy and safety of the fixed-dose combination (FDC) of Efonidipine and S (-) Metoprolol in adult patients with hypertension. Study Design: Multicentric, double-blind, randomized, parallel, comparative Phase III trial. Methodology: This clinical trial was conducted at five geographically distributed sites across India and enrolled 240 hypertensive patients. They were randomized (1:1) to receive either FDC of Efonidipine 40 mg + S (-) Metoprolol 25 mg tablet (E+S(-)M group) or FDC of Cilnidipine 10 mg + Metoprolol 50 mg tablet (C+M group) once daily for 90 days. Patients were evaluated for changes in their blood pressure (BP) from baseline to Day 30, 60 and 90. The study site staff, investigator and patients were blinded to the treatment allocation. Blood pressure was recorded as the mean of 3 consecutive measurements taken in a sitting position. Patients achieving target BP (<140/90 mmHg) were evaluated and the safety and tolerability were assessed based on the incidences of adverse events (AEs). Results: This study focused on evaluating the mean Systolic BP (SBP) and Diastolic BP (DBP) reduction from baseline to Day 30, 60 and 90. At baseline, patients had a mean (±SD) SBP and DBP of 154.60 (±11.33) mmHg and 98.68 (±8.18) mmHg respectively. After 30 days of the E+S(-)M treatment, the mean SBP/DBP was 136.06±10.55/ 86.68±5.51 mmHg (p<0.0001) and on Day 60 it was 129.48±10.51/ 84.17±5.51mmHg (P <0.0001), corresponding to mean reductions in SBP/DBP of 18.09/11.66 and 24.78/14.17 mmHg, respectively. There was a statistically significant (p <0.0001) reduction to 123.59 ± 15.21 mmHg in SBP and 82.38 ± 5.05 mmHg in DBP observed on Day 90 as compared to baseline. Post-treatment with E+S(-)M group, SBP/DBP reduction of 31.01/16.29 mmHg in hypertensive patients was observed. A total of 95% of the patients achieved a pre-defined target BP <140/90 mmHg on the administration of E+S(-)M. Furthermore, it was observed that 93% of Stage I and 96% of Stage II hypertensive patients achieved the target BP goal. A total of 5.78% of patients experienced adverse events (AEs) in the E+S(-)M group which was similar to that of C+M group. All AEs were mild in severity and resolved without any sequelae at the end of the study. No unexpected adverse events were reported, and the E+S(-)M dosage regimen was well tolerated by the patients. Both the treatment groups were non-inferior to each other. Conclusion: The study results demonstrated clinically meaningful reductions in blood pressure after administration of FDC of Efonidipine 40 mg + S(-) Metoprolol 25 mg over a period of 90 days. The treatment was efficacious, safe, and well‑tolerated in the study population.

Hypertension fixed-dose combination efonidipine S(-)Metoprolol blood pressure

References (31)

  1. 1 Correspondence - Tranexamic acid for traumatic brain injury [DOI]
  2. 2 2018 ESC/ESH Guidelines for the management of arterial hypertension [DOI]
  3. 3 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults [DOI]
  4. 4 Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants [DOI]
  5. 5 Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis [DOI]
  6. 6 The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014) [DOI]
  7. 7 Combination therapy in hypertension [DOI]
  8. 8 Combination Therapy in Hypertension [DOI]
  9. 9 Combination therapy in the treatment of hypertension [DOI]
  10. 10 A review on prescribing patterns of antihypertensive drugs [DOI]
  11. 11 Two-Drug Combinations as First-Step Antihypertensive Treatment [DOI]
  12. 12 Fixed‐dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications [DOI]
  13. 13 Prevalence, Awareness, Treatment, and Control of Hypertension in Young Adults (20–39 Years) in Kerala, South India [DOI]
  14. 14 Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment [DOI]
  15. 15 Fixed‐dose vs free‐dose combinations for the management of hypertension—An analysis of 81 958 patients [DOI]
  16. 16 Current perspectives on combination therapy in the management of hypertension [DOI]
  17. 17 Efonidipine Hydrochloride: A Dual Blocker of L‐ and T‐Type Ca2+ Channels [DOI]
  18. 18 A Factorial Study of Combination Hypertension Treatment With Metoprolol Succinate Extended Release and Felodipine Extended ReleaseResults of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT) [DOI]
  19. 19 Combining Other Antihypertensive Drugs With β-Blockers in Hypertension: A Focus on Safety and Tolerability [DOI]
  20. 20 Clinical Efficacy of Efonidipine Hydrochloride, a T-type Calcium Channel Inhibitor, on Sympathetic Activities. Examination Using Spectral Analysis of Heart Rate/Blood Pressure Variabilities and 123I-Metaiodobenzylguanidine Myocardial Scintigraphy. [DOI]
  21. 21 Comparative Efficacy of Two Different β‐Blockers on 24‐Hour Blood Pressure Control [DOI]
  22. 22 Rediscovering Chirality - Role of S-Metoprolol in Cardiovascular Disease Management.
  23. 23 A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension [DOI]
  24. 24 Essential hypertension [DOI]
  25. 25 Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris [DOI]
  26. 26 Fixed-dose combination therapy to improve hypertension treatment and control in Latin America [DOI]
  27. 27 Effect of fixed dose combinations of metoprolol and amlodipine in essential hypertension: MARS – A randomized controlled trial [DOI]
  28. 28 Efficacy and tolerability of fixed dose combination of metoprolol and amlodipine in Indian patients with essential hypertension [DOI]
  29. 29 Frequency-dependent blockade of T-type Ca2+ current by efonidipine in cardiomyocytes [DOI]
  30. 30 Combination drug therapy for hypertension
  31. 31 The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

53

Page views

0

PDF downloads

29

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.